Skip to main content
Top
Published in: Endocrine 3/2010

01-12-2010 | Original Article

The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions

Authors: Yasuhiro Hamada, Sohei Kitazawa, Riko Kitazawa, Keiji Kono, Shunsuke Goto, Hirotaka Komaba, Hideki Fujii, Yasuhiko Yamamoto, Hiroshi Yamamoto, Makoto Usami, Masafumi Fukagawa

Published in: Endocrine | Issue 3/2010

Login to get access

Abstract

It has been reported that AGEs and the receptor for AGEs (RAGEs) have been linked to the pathogenesis of diabetic microangiopathy. However, the relationship between RAGE and alteration in bone metabolism is unclear. Therefore, in order to determine the role of RAGE in bone metabolism, we investigated the effects of RAGE deletion on bone metabolism under physiological and diabetic conditions using RAGE knockout mice (RAGE-KO). Eight-week-old male RAGE-KO and wild-type littermates (WT) were intraperitoneally injected with either streptozotocin or vehicle. Mice were classified into four groups: (1) nondiabetic WT; (2) nondiabetic RAGE-KO; (3) diabetic WT; and (4) diabetic RAGE-KO. After 12 weeks of streptozotocin or vehicle treatment, the physical properties of femora and the static and dynamic parameters of bone histomorphometry of tibiae were assessed. The deletion of RAGE affected neither body weights nor hemoglobin A1c levels. RAGE deletion resulted in increased bone mineral density due to decreased osteoclast function under physiological conditions that is no accumulation of AGEs. In contrast, lacking RAGE did not affect the alteration in bone metabolism under diabetic conditions, suggesting that AGEs–RAGE interaction may not be involved in the pathogenesis of diabetic osteopenia, although RAGE plays a crucial role in bone metabolism.
Literature
1.
go back to reference M.E. Levin, V.C. Boisseau, L.V. Avioli, Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N. Engl. J. Med. 294(5), 241–245 (1976)CrossRefPubMed M.E. Levin, V.C. Boisseau, L.V. Avioli, Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N. Engl. J. Med. 294(5), 241–245 (1976)CrossRefPubMed
2.
go back to reference L. Forsén, H.E. Meyer, K. Midthjell, T.H. Edna, Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. Diabetologia 42(8), 920–925 (1999)CrossRefPubMed L. Forsén, H.E. Meyer, K. Midthjell, T.H. Edna, Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. Diabetologia 42(8), 920–925 (1999)CrossRefPubMed
3.
go back to reference A.M. Herskind, K. Christensen, K. Nørgaard-Andersen, J.F. Andersen, Diabetes mellitus and healing of closed fractures. Diabete Metab 18(1), 63–64 (1992)PubMed A.M. Herskind, K. Christensen, K. Nørgaard-Andersen, J.F. Andersen, Diabetes mellitus and healing of closed fractures. Diabete Metab 18(1), 63–64 (1992)PubMed
4.
go back to reference Y. Hamada, S. Kitazawa, R. Kitazawa, H. Fujii, M. Kasuga, M. Fukagawa, Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone 40(5), 1408–1414 (2007)CrossRefPubMed Y. Hamada, S. Kitazawa, R. Kitazawa, H. Fujii, M. Kasuga, M. Fukagawa, Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone 40(5), 1408–1414 (2007)CrossRefPubMed
5.
go back to reference H. Fujii, Y. Hamada, M. Fukagawa, Bone formation in spontaneously diabetic Torii-newly established model of non-obese type 2 diabetes rats. Bone 42(2), 372–379 (2008)CrossRefPubMed H. Fujii, Y. Hamada, M. Fukagawa, Bone formation in spontaneously diabetic Torii-newly established model of non-obese type 2 diabetes rats. Bone 42(2), 372–379 (2008)CrossRefPubMed
6.
go back to reference Y. Hamada, H. Fujii, R. Kitazawa, J. Yodoi, S. Kitazawa, M. Fukagawa, Thioredoxin-1 overexpression in transgenic mice attenuates streptozotocin-induced diabetic osteopenia: a novel role of oxidative stress and therapeutic implications. Bone 44(5), 936–941 (2009)CrossRefPubMed Y. Hamada, H. Fujii, R. Kitazawa, J. Yodoi, S. Kitazawa, M. Fukagawa, Thioredoxin-1 overexpression in transgenic mice attenuates streptozotocin-induced diabetic osteopenia: a novel role of oxidative stress and therapeutic implications. Bone 44(5), 936–941 (2009)CrossRefPubMed
7.
go back to reference Y. Hamada, H. Fujii, M. Fukagawa, Role of oxidative stress in diabetic bone disorder. Bone 45(Suppl 1), S35–S38 (2009)CrossRefPubMed Y. Hamada, H. Fujii, M. Fukagawa, Role of oxidative stress in diabetic bone disorder. Bone 45(Suppl 1), S35–S38 (2009)CrossRefPubMed
8.
go back to reference M. Brownlee, Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865), 813–820 (2001)CrossRefPubMed M. Brownlee, Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865), 813–820 (2001)CrossRefPubMed
9.
go back to reference T. Miyata, K. Notoya, K. Yoshida, K. Horie, K. Maeda, K. Kurokawa et al., Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J. Am. Soc. Nephrol. 8(2), 260–270 (1997)PubMed T. Miyata, K. Notoya, K. Yoshida, K. Horie, K. Maeda, K. Kurokawa et al., Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J. Am. Soc. Nephrol. 8(2), 260–270 (1997)PubMed
10.
go back to reference M. Alikhani, Z. Alikhani, C. Boyd, C.M. MacLellan, M. Raptis, R. Liu et al., Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40(2), 345–353 (2007)CrossRefPubMed M. Alikhani, Z. Alikhani, C. Boyd, C.M. MacLellan, M. Raptis, R. Liu et al., Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40(2), 345–353 (2007)CrossRefPubMed
11.
go back to reference G. Hein, R. Wiegand, G. Lehmann, G. Stein, S. Franke, Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42(10), 1242–1246 (2003)CrossRefPubMed G. Hein, R. Wiegand, G. Lehmann, G. Stein, S. Franke, Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42(10), 1242–1246 (2003)CrossRefPubMed
12.
go back to reference M. Shiraki, T. Kuroda, S. Tanaka, M. Saito, M. Fukunaga, T. Nakamura, Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J. Bone Miner. Metab. 26(1), 93–100 (2008)CrossRefPubMed M. Shiraki, T. Kuroda, S. Tanaka, M. Saito, M. Fukunaga, T. Nakamura, Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J. Bone Miner. Metab. 26(1), 93–100 (2008)CrossRefPubMed
13.
go back to reference A.M. Schmidt, M. Vianna, M. Gerlach, J. Brett, J. Ryan, J. Kao et al., Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267(21), 14987–14997 (1992)PubMed A.M. Schmidt, M. Vianna, M. Gerlach, J. Brett, J. Ryan, J. Kao et al., Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267(21), 14987–14997 (1992)PubMed
14.
go back to reference M. Neeper, A.M. Schmidt, J. Brett, S.D. Yan, F. Wang, Y.C. Pan et al., Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267(21), 14998–15004 (1992)PubMed M. Neeper, A.M. Schmidt, J. Brett, S.D. Yan, F. Wang, Y.C. Pan et al., Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267(21), 14998–15004 (1992)PubMed
15.
go back to reference J. Brett, A.M. Schmidt, S.D. Yan, Y.S. Zou, E. Weidman, D. Pinsky et al., Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6), 1699–1712 (1993)PubMed J. Brett, A.M. Schmidt, S.D. Yan, Y.S. Zou, E. Weidman, D. Pinsky et al., Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6), 1699–1712 (1993)PubMed
16.
17.
go back to reference W.F. Owen Jr., F.F. Hou, R.O. Stuart, J. Kay, J. Boyce, G.M. Chertow et al., β2-Microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int. 53(5), 1365–1373 (1998)CrossRefPubMed W.F. Owen Jr., F.F. Hou, R.O. Stuart, J. Kay, J. Boyce, G.M. Chertow et al., β2-Microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int. 53(5), 1365–1373 (1998)CrossRefPubMed
18.
go back to reference S. Kume, S. Kato, S. Yamagishi, Y. Inagaki, S. Ueda, N. Arima et al., Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J. Bone Miner. Res. 20(9), 1647–1658 (2005)CrossRefPubMed S. Kume, S. Kato, S. Yamagishi, Y. Inagaki, S. Ueda, N. Arima et al., Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J. Bone Miner. Res. 20(9), 1647–1658 (2005)CrossRefPubMed
19.
go back to reference K. Abeyama, D.M. Stern, Y. Ito, K. Kawahara, Y. Yoshimoto, M. Tanaka et al., The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 115(5), 1267–1274 (2005)PubMed K. Abeyama, D.M. Stern, Y. Ito, K. Kawahara, Y. Yoshimoto, M. Tanaka et al., The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 115(5), 1267–1274 (2005)PubMed
20.
go back to reference K.M. Myint, Y. Yamamoto, T. Doi, I. Kato, A. Harashima, H. Yonekura et al., RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55(9), 2510–2522 (2006)CrossRefPubMed K.M. Myint, Y. Yamamoto, T. Doi, I. Kato, A. Harashima, H. Yonekura et al., RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55(9), 2510–2522 (2006)CrossRefPubMed
21.
go back to reference A.M. Parfitt, M.K. Drezner, F.H. Glorieux, J.A. Kanis, H. Malluche, P.J. Meunier et al., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2(6), 595–610 (1987)CrossRefPubMed A.M. Parfitt, M.K. Drezner, F.H. Glorieux, J.A. Kanis, H. Malluche, P.J. Meunier et al., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2(6), 595–610 (1987)CrossRefPubMed
22.
go back to reference Z. Zhou, D. Immel, C.X. Xi, A. Bierhaus, X. Feng, L. Mei et al., Regulation of osteoclast function and bone mass by RAGE. J. Exp. Med. 203(4), 1067–1080 (2006)CrossRefPubMed Z. Zhou, D. Immel, C.X. Xi, A. Bierhaus, X. Feng, L. Mei et al., Regulation of osteoclast function and bone mass by RAGE. J. Exp. Med. 203(4), 1067–1080 (2006)CrossRefPubMed
23.
go back to reference B.K. Philip, P.J. Childress, A.G. Robling, A. Heller, P.P. Nawroth, A. Bierhaus et al., RAGE supports parathyroid hormone-induced gains in femoral trabecular bone. Am. J. Physiol. Endocrinol. Metab. 298(3), 714–725 (2010)CrossRef B.K. Philip, P.J. Childress, A.G. Robling, A. Heller, P.P. Nawroth, A. Bierhaus et al., RAGE supports parathyroid hormone-induced gains in femoral trabecular bone. Am. J. Physiol. Endocrinol. Metab. 298(3), 714–725 (2010)CrossRef
24.
go back to reference T. Kislinger, C. Fu, B. Huber, W. Qu, A. Taguchi, S. Du Yan et al., N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274(44), 31740–31749 (1999)CrossRefPubMed T. Kislinger, C. Fu, B. Huber, W. Qu, A. Taguchi, S. Du Yan et al., N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274(44), 31740–31749 (1999)CrossRefPubMed
25.
go back to reference O. Hori, J. Brett, T. Slattery, R. Cao, J. Zhang, J.X. Chen et al., The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270(43), 25752–25761 (1995)CrossRefPubMed O. Hori, J. Brett, T. Slattery, R. Cao, J. Zhang, J.X. Chen et al., The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270(43), 25752–25761 (1995)CrossRefPubMed
26.
go back to reference A. Taguchi, D.C. Blood, G. del Toro, A. Canet, D.C. Lee, W. Qu et al., Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405(6784), 354–360 (2000)CrossRefPubMed A. Taguchi, D.C. Blood, G. del Toro, A. Canet, D.C. Lee, W. Qu et al., Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405(6784), 354–360 (2000)CrossRefPubMed
27.
go back to reference M.A. Hofmann, S. Drury, C. Fu, W. Qu, A. Taguchi, Y. Lu et al., RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97(7), 889–901 (1999)CrossRefPubMed M.A. Hofmann, S. Drury, C. Fu, W. Qu, A. Taguchi, Y. Lu et al., RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97(7), 889–901 (1999)CrossRefPubMed
28.
go back to reference S.D. Yan, X. Chen, J. Fu, M. Chen, H. Zhu, A. Roher et al., RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature 382(6593), 685–691 (1996)CrossRefPubMed S.D. Yan, X. Chen, J. Fu, M. Chen, H. Zhu, A. Roher et al., RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature 382(6593), 685–691 (1996)CrossRefPubMed
29.
go back to reference T. Chavakis, A. Bierhaus, N. Al-Fakhri, D. Schneider, S. Witte, T. Linn et al., The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 198(10), 1507–1515 (2003)CrossRefPubMed T. Chavakis, A. Bierhaus, N. Al-Fakhri, D. Schneider, S. Witte, T. Linn et al., The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 198(10), 1507–1515 (2003)CrossRefPubMed
30.
go back to reference L.G. Bucciarelli, T. Wendt, L. Rong, E. Lalla, M.A. Hofmann, M.T. Goova et al., RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell. Mol. Life Sci. 59(7), 1117–1128 (2002)CrossRefPubMed L.G. Bucciarelli, T. Wendt, L. Rong, E. Lalla, M.A. Hofmann, M.T. Goova et al., RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell. Mol. Life Sci. 59(7), 1117–1128 (2002)CrossRefPubMed
31.
go back to reference A.M. Schmidt, S.D. Yan, J.L. Wautier, D. Stern, Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84(5), 489–497 (1999)PubMed A.M. Schmidt, S.D. Yan, J.L. Wautier, D. Stern, Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84(5), 489–497 (1999)PubMed
32.
go back to reference H. Yonekura, Y. Yamamoto, S. Sakurai, R.G. Petrova, M.J. Abedin, H. Li et al., Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370, 1097–1109 (2003)CrossRefPubMed H. Yonekura, Y. Yamamoto, S. Sakurai, R.G. Petrova, M.J. Abedin, H. Li et al., Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370, 1097–1109 (2003)CrossRefPubMed
33.
go back to reference C. Schlueter, S. Hauke, A.M. Flohr, P. Rogalla, J. Bullerdiek, Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing? Biochim. Biophys. Acta 1630(1), 1–6 (2003)PubMed C. Schlueter, S. Hauke, A.M. Flohr, P. Rogalla, J. Bullerdiek, Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing? Biochim. Biophys. Acta 1630(1), 1–6 (2003)PubMed
34.
go back to reference Q. Ding, J.N. Keller, Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci. Lett. 373(1), 67–72 (2005)CrossRefPubMed Q. Ding, J.N. Keller, Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci. Lett. 373(1), 67–72 (2005)CrossRefPubMed
35.
go back to reference A. Bierhaus, P.M. Humpert, M. Morcos, T. Wendt, T. Chavakis, B. Arnold et al., Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83(11), 876–886 (2005)CrossRefPubMed A. Bierhaus, P.M. Humpert, M. Morcos, T. Wendt, T. Chavakis, B. Arnold et al., Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83(11), 876–886 (2005)CrossRefPubMed
36.
go back to reference E. Lalla, I.B. Lamster, M. Feit, L. Huang, A. Spessot, W. Qu et al., Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J. Clin. Invest. 105(8), 1117–1124 (2000)CrossRefPubMed E. Lalla, I.B. Lamster, M. Feit, L. Huang, A. Spessot, W. Qu et al., Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J. Clin. Invest. 105(8), 1117–1124 (2000)CrossRefPubMed
37.
go back to reference J.L. Wautier, C. Zoukourian, O. Chappey, M.P. Wautier, P.J. Guillausseau, R. Cao et al., Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97(1), 238–243 (1996)CrossRefPubMed J.L. Wautier, C. Zoukourian, O. Chappey, M.P. Wautier, P.J. Guillausseau, R. Cao et al., Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97(1), 238–243 (1996)CrossRefPubMed
38.
go back to reference L. Park, K.G. Raman, K.J. Lee, Y. Lu, L.J. Ferran Jr., W.S. Chow et al., Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4(9), 1025–1031 (1998)CrossRefPubMed L. Park, K.G. Raman, K.J. Lee, Y. Lu, L.J. Ferran Jr., W.S. Chow et al., Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4(9), 1025–1031 (1998)CrossRefPubMed
Metadata
Title
The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions
Authors
Yasuhiro Hamada
Sohei Kitazawa
Riko Kitazawa
Keiji Kono
Shunsuke Goto
Hirotaka Komaba
Hideki Fujii
Yasuhiko Yamamoto
Hiroshi Yamamoto
Makoto Usami
Masafumi Fukagawa
Publication date
01-12-2010
Publisher
Springer US
Published in
Endocrine / Issue 3/2010
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-010-9390-9

Other articles of this Issue 3/2010

Endocrine 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine